OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2B
OpenAI researcher Miles Wang is reportedly leaving the company to launch a startup focused on AI-driven drug discovery. The venture is seeking significant funding at a $2 billion valuation, reflecting a broader trend of investor interest in applying artificial intelligence to life sciences.
Why it matters
The move highlights the growing trend of top AI talent leaving major labs to pursue specialized, high-value applications in biotechnology and medicine.
Miles Wang , an OpenAI researcher whose work includes using AI to accelerate scientific and biological discovery, is leaving the ChatGPT maker to launch a new startup focused on developing AI models for drug discovery, according to four people with knowledge of his plans. Several other OpenAI researchers are expected to join the new company.
Wang is in talks to raise about $200 million at a $2 billion valuation, two of the people said. Lightspeed is in discussions to lead the funding round, according to the people. Talks are ongoing, the deal may not be final and details could change.
Wang disputed the story’s funding figures and description of the company but did not specify the correct numbers or details. Lightspeed didn’t respond to a request for comment.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in